<DOC>
	<DOCNO>NCT00259727</DOCNO>
	<brief_summary>The purpose study determine mechanism HIV protease inhibitor contribute development diabetes HIV-infected patient . The investigator propose HIV protease inhibitor impair insulin secretion increase production glucose liver .</brief_summary>
	<brief_title>The Study HIV Protease Inhibitors Their Effects Glucose Metabolism</brief_title>
	<detailed_description>HIV protease inhibitor ( PIs ) associate type 2 diabetes . To design future HIV drug least adverse metabolic effect , necessary identify disorder glucose metabolism PI therapy . Previously PIs show acutely induce insulin resistance periphery . Preliminary data show PIs also impair insulin secretion increase hepatic glucose production human . These lesion key contributor development type 2 diabetes . Due difficulty separate factor related HIV infection direct effect PIs , effective design study HIV-negative subject define direct effect PIs liver pancreas glucose metabolism : Specific Aim 1 : To determine PIs acutely inhibit insulin secretion human ; randomize , double-blind , placebo-controlled trial perform healthy normal volunteer give either single dose PI placebo use hyperglycemic clamp ass insulin secretion relation insulin sensitivity . Specific Aim 2 : To determine PIs acutely increase hepatic glucose production , glycogenolysis , gluconeogenesis ; measurement assess fast hyperinsulinemic state use stable isotope analysis technique . Samples already collect double-blind , placebo-controlled trial effect single dose PI insulin sensitivity euglycemic hyperinsulinemic clamp . Specific Aim 3 : To determine mechanism certain PIs increase hepatic glucose production ; infusion somatostatin fast state hyperinsulinemic state use suppress effect glucagon . Subjects undergo randomize , double-blind , placebo-controlled trial single dose PI placebo insulin sensitivity use euglycemic hyperinsulinemic clamp . Somatostatin , glucagon , growth hormone infuse clamp study . Hepatic glucose production , glycogenolysis , gluconeogenesis assess use stable isotope tracer technique . Results compare PIs acutely give absence somatostatin , state Specific Aim 2 . Determination effect PI therapy allow clinician identify patient may particular risk develop diabetes certain PIs treat effectively . In future , drug treatment HIV develop avoid disorder glucose metabolism .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<criteria>Healthy , HIVnegative volunteer age 1872 year Any subject state know associated insulin resistance , impair fast glucose ( glucose &gt; 110 mg/dl ) , overweight ( body mass index [ BMI ] &gt; 27 ) , dyslipidemia ( triglyceride &gt; 150 mg/dl ) , hypertension ( blood pressure [ BP ] &gt; 130/85 mmHg medication ) , renal disease , systemic use glucocorticoid , growth hormone , niacin , antipsychotic . Women test pregnancy immediately prior study exclude pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Amprenavir</keyword>
	<keyword>Glucagon</keyword>
	<keyword>HIV Protease inhibitor</keyword>
	<keyword>Indinavir</keyword>
	<keyword>Lopinavir</keyword>
	<keyword>Ritonavir</keyword>
</DOC>